Comparative analysis confirms pharmacological equivalence of (S)- and (S/R)-FAPI-46/-74 mixtures, enhancing regulatory confidence and reproducibility.
These findings provide important validation that current clinical (S/R)-mixtures of FAPI-46/-74 exhibit pharmacokinetic and pharmacodynamic behavior comparable to pure (S)-enantiomers, supporting regulatory confidence and cross-trial reproducibility in the global FAPI-46/-74 imaging landscape.
No takes yet. Share an insight, caveat, or question.
Staniszewska et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: